Compounds for the inhibition of histone deacetylase
AssigneeNaturewise Biotech & Medicals Corporation
InventorsChung-Yang Huang, Chia-Nan Chen, Wei-Jan Huang, Chih-Hsiang Huang, Li-Ling Chi, Chiou-Ping You
Life of this patent
Estimating the term…
Abstract
The invention relates to a compound represented by the following formula (I): and pharmaceutically acceptable salts, stereoisomers, enantiomers, prodrugs and solvates thereof. The compounds are useful as an agent for enhancing the neurite outgrowth and preventing or treating of diseases associated with HDAC in particular, tumor or cell proliferative diseases. In particular, the compounds of the invention can be used as an agent for anti-neurodegenerative diseases and human spinal muscular atrophy (SMA).
Claims16
A compound represented by the following formula (I):
- wherein
- R1 and R2 are each independently O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, O-alkynyl, S-alkynyl, N-alkynyl, O—C3-8cycloalkyl, S—C3-8cycloalkyl, N—C3-8cycloalkyl, O-unsaturated 5- to 10-membered monocyclic or bicyclic ring, S-unsaturated 5- to 10-membered monocyclic or bicyclic ring, N-unsaturated 5- to 10-membered monocyclic or bicyclic ring, alkyl, alkylenyl, alkynyl, C3-8cycloalkyl, an unsaturated 5- to 10-membered monocyclic or bicyclic ring or a saturated or unsaturated 5- to 10-membered heterocyclic ring comprising at least one ring heteroatom selected from the group consisting of:
- N, O and S;
- or
- R1 and R2 can together form dioxolane;
- R3 is O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, O-alkynyl, S-alkynyl, N-alkynyl, O—C3-8cycloalkyl, S—C3-8-cycloalkyl, N—C3-8cycloalkyl, O-unsaturated 5- to 10-membered monocyclic or bicyclic ring, S-unsaturated 5- to 10-membered monocyclic or bicyclic ring, N-unsaturated 5- to 10-membered monocyclic or bicyclic ring, alkyl, alkylenyl, alkynyl, C3-8cycloalkyl, an unsaturated 5- to 10-membered monocyclic or bicyclic ring or a saturated or unsaturated 5- to 10-membered heterocyclic ring comprising at least one ring heteroatom selected from the group consisting of:
- N, O and S;
- R4 is OH, OC(═O)alkyl, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, O-alkynyl, S-alkynyl, N-alkynyl, O—C3-8cycloalkyl, S—C3-8cycloalkyl, N—C3-8cycloalkyl, O-unsaturated 5- to 10-membered monocyclic or bicyclic ring, S-unsaturated 5- to 10-membered monocyclic or bicyclic ring, N-unsaturated 5- to 10-membered monocyclic or bicyclic ring, alkyl, alkylenyl, alkynyl, C3-8cycloalkyl, an unsaturated 5- to 10-membered monocyclic or bicyclic ring or a saturated or unsaturated 5- to 10-membered heterocyclic ring comprising at least one ring heteroatom selected from the group consisting of:
- N, O and S;
- R5 is C4-16 alkyl or C4-16alkenyl unsubstituted or substituted with one or more OH, halogen, CN, NO, N3, NH2, CHO, OR9, SR9, NR9, or COOR9;
- R6 is C2-12 alkyl or C2-12 alkenyl unsubstituted or substituted with one or more OH, halogen, CN, NO, N3, NH2, CHO, OR9, SR9, or NR9;
- R7 is hydrogen, halogen, OH, NH2, COOH, CHO, CN, NO, ═O, or R7 and R8 may together form a double bond, a C3-6cycloalkyl, or a 5- to 10-membered heterocyclic ring comprising at least a heteroatom selected from the group consisting of N, O and S;
- R8 is hydrogen, halogen, OH, NH2, COOH, CHO, CN or NO;
- R9 is phenyl, C(═O)R10 or C(═O)OR10;
- and
- R10 is OH, NHOH or NH2;
- wherein both R5 and R6 are not simultaneously unsubstituted alkyl or alkenyl;
- or pharmaceutically acceptable salts, stereoisomers, enantiomers, prodrugs or solvates thereof.
Dependencies are inferred from the claim text.